The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.
Update: 2024-05-29
Description
What's preventing insurers from covering the specialized care of patients with nano-rare mutations, thereby expanding access to available treatment options? Is it the population size, cost, or perceived risk? Given that the initial discovery of nano-rare mutations is relatively recent, paving the way for this population requires a nuanced approach to overcome various obstacles. Alan Lotvin, M.D., CEO and co-founder of Sequel Med Tech, and former president of CVS Caremark, conceptualizes these hurdles.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
